Mangoceuticals, Inc.
MGRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | -15.8% | 8,083.2% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 61.7% | 59% | 54.3% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $6 | $3 | $2 | $0 |
| SG&A Expenses | $8 | $5 | $2 | $0 |
| Sales & Mktg Exp. | $1 | $2 | $0 | $0 |
| Other Operating Expenses | $0 | $4 | $0 | $0 |
| Operating Expenses | $8 | $10 | $2 | $0 |
| Operating Income | -$8 | -$9 | -$2 | -$0 |
| % Margin | -1,294.4% | -1,260.3% | -22,279.7% | – |
| Other Income/Exp. Net | -$1 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$9 | -$9 | -$2 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$9 | -$2 | -$0 |
| % Margin | -1,413.6% | -1,259.4% | -22,352.1% | – |
| EPS | -4.399 | -8.58 | -1.731 | -0.018 |
| % Growth | 48.7% | -395.7% | -9,679.1% | – |
| EPS Diluted | -4.399 | -8.58 | -1.731 | -0.018 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$8 | -$8 | -$2 | -$0 |
| % Margin | -1,292.8% | -1,106.4% | -22,236.5% | – |